^
Association details:
| Biomarker: | PD-L1 negative |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Immunotherapy or antiangiogenic therapy plus chemotherapy as first-line treatment of patients with PD-L1(-) advanced non-squamous non-small cell lung cancer in a Chinese cohort
Published date:
05/22/2023
Excerpt:
Our study aimed to compare two first-line regimens for patients with advanced nonsquamous NSCLC who were negative for PD-L1....Patients who received bevacizumab (Roche) at 7.5 mg/kg plus pemetrexed and cisplatin in 3-week cycles were assigned to Group A....The mPFS of the patients in Group A was 9.8 months (95% CI: 6.0–13.7) and in Group B was 6.7 months (95% CI: 5.5–7.8), respectively (Figure 2A), and there is a statistical difference between the groups (p = 0.025).
Secondary therapy:
cisplatin + pemetrexed
DOI:
https://doi.org/10.1002/cam4.6101
